Cardiac complication after experimental human malaria infection: a case report
<p>Abstract</p> <p>A 20 year-old healthy female volunteer participated in a clinical Phase I and IIa safety and efficacy trial with candidate malaria vaccine <it>Pf</it>LSA-3-rec adjuvanted with aluminium hydroxide. Eleven weeks after the third and last immunization she...
Main Authors: | Druilhe Pierre, Stalenhoef Anton, Pop Gheorghe, Wiersma Jorien, Roestenberg Meta, de Mast Quirijn, Nieman An-Emmie, Sauerwein Robert, van der Ven André |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-12-01
|
Series: | Malaria Journal |
Online Access: | http://www.malariajournal.com/content/8/1/277 |
Similar Items
-
Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans.
by: Anne C Teirlinck, et al.
Published: (2011-12-01) -
Comparison of clinical and parasitological data from controlled human malaria infection trials.
by: Meta Roestenberg, et al.
Published: (2012-01-01) -
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
by: Meta Roestenberg, et al.
Published: (2008-01-01) -
Comparison of clinical and parasitological data from controlled human malaria infection trials.
by: Roestenberg, M, et al.
Published: (2012) -
Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers.
by: Judith Brouwers, et al.
Published: (2014-01-01)